In fact, in insulin treated T2DM patients with stable glycemic control, the intrahepatic triglyceride content was the factor most strongly correlated with the daily insulin dose, the inter-individual variation in insulin requirements and with the ability of insulin to suppress hepatic glucose production [68] Many authors suggest that intrahepatic triglyceride content is more important than visceral fat content in inducing adverse metabolic phenotype in obesity [69–71]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.